Search

Sitagliptin

The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[FDA label,A2255]. … Sitagliptin was granted FDA approval on October 16, 2006[L6061].

Paroxetine

[T653] It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham. … Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class.

Diamorphine

As heroin, it is illegal to manufacture, possess, or sell in the United States and the UK. However, under the name diamorphine, heroin is a legal prescription drug in the United Kingdom. … Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed) Internationally, diamorphine is controlled under Schedules I and IV of the Single Convention on Narcotic Drugs.

Octisalate

It does not protect against UVA. Octyl salicylate is used to augment the UVB protection in a sunscreen. … Octyl salicylate appears to have a good safety profile. It covers wavelength in the range 295-315 nm, peak at 307-310 nm. It is an ester of salicylic acid and 2-ethylhexanol.

Ticagrelor

[A2903] Unlike [clopidogrel], ticagrelor is not a prodrug.[A2903] It is marketed by Astra Zeneca as Brilinta in the US[L14201] and Brilique or Possia in the EU,[L14207]. … Ticagrelor was granted EMA approval on 3 December 2010.[L14207] Ticagrelor was granted FDA approval on 20 July 2011.[L14201]

Fumaric acid

Desmopressin

It is considered a first-line therapy for central diabetes insipidus but is ineffective in patients with nephrogenic diabetes insipidus, where the kidneys are non-responsive to the hormone [A275458, L56105 … Additionally, it serves as a critical hematologic agent for the management of mild hemophilia A and von Willebrand disease (Type I) by transiently increasing levels of clotting factors [A31662, A275458

Carbocisteine

[A230993] Carbocisteine is currently not FDA or Health Canada approved, but is approved for use in Asia, Europe, and South America. … Carbocisteine is a mucolytic drug that alleviates respiratory symptoms and infections by reducing the viscosity of mucus, allowing it to be expelled.

Cephalexin

[A179071] Cephalexin is used to treat a number of susceptible bacterial infections through inhibition of cell wall synthesis.[A179083,L6547] Cephalexin was approved by the FDA on 4 January 1971.